Suchergebnisse - (Person:"Mao, Xing-Gang")

PubPharm (53)

11

Malignant Intracranial High Grade Glioma and Current Treatment Strategy

enthalten in: Current cancer drug targets | 2019

von Zhang, X. | Zhang, W. | Mao, X. | +3

12

Advances in the delivery of antisense oligonucleotides for combating bacterial infectious diseases

enthalten in: Nanomedicine : nanotechnology, biology, and medicine | 2018

von Xue, X. | Mao, X. | Zhou, Y. | +6

13

Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma

enthalten in: Oncotarget | 2016

von Mao, X. | Wang, C. | Liu, D. | +13

14

The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma

enthalten in: Cancer letters | 2016

von Kaur, H. | Ali, S. | Huey, L. | +8

15

The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma

enthalten in: Cancer letters | 2016

von Kaur, H. | Ali, S. | Huey, L. | +8

16

Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets

enthalten in: Biomarker Research | 2015

von Mao, J. | Liu, J. | Guo, G. | +2

17

Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets

enthalten in: Biomarker Research | 2015

von Mao, J. | Liu, J. | Guo, G. | +2

18

A potent and selective antimicrobial poly(amidoamine) dendrimer conjugate with LED209 targeting QseC receptor to inhibit the virulence genes of gram negative bacteria

enthalten in: Nanomedicine : nanotechnology, biology, and medicine | 2015

von Xue, X. | Mao, X. | Li, Z. | +6

19

Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target

enthalten in: Oncotarget | 2015

von Weingart, M. | Roth, J. | Hutt-Cabezas, M. | +16

20

Glioblastoma vasculogenic mimicry : signaling pathways progression and potential anti-angiogenesis targets

enthalten in: Biomarker research | 2015

von Mao, J. | Liu, J. | Guo, G. | +2